Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

被引：16
|
作者：
Lee, Elizabeth K. [1 ]
Tan-Wasielewski, Zhenying [2 ]
Matulonis, Ursula A. [1 ,3 ]
Birrer, Michael J. [4 ,6 ]
Wright, Alexi A. [1 ,3 ]
Horowitz, Neil [3 ,5 ]
Konstantinopoulos, Panagiotis A. [1 ,3 ]
Curtis, Jennifer [3 ]
Liu, Joyce F. [1 ,3 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Canc Ctr, Med Gynecol Oncol, Boston, MA 02114 USA
[5] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA
[6] Univ Alabama Birmingham, Div Hematol Oncol, ONeal Comprehens Canc Ctr, Birmingham, AL USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2019年 / 29卷
关键词：
HDAC inhibitor; HDAC6; Ovarian cancer; Peripheral neuropathy; Paclitaxel; Taxane; HISTONE DEACETYLASE INHIBITORS; PATHWAYS;
D O I：
10.1016/j.gore.2019.07.010
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies. Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.
引用
收藏
页码：118 / 122
页数：5
相关论文
共 50 条
  • [1] Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer (vol 29, pg 118, 2019)
    Lee, E. K.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 35
  • [2] A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Burger, R. A.
    Hamilton, E.
    Corr, B. R.
    Naumann, R. W.
    Wenham, R. M.
    Morgan, M. A.
    Stagg, R.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 14 - 15
  • [3] Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Fu, Siqing
    Corr, Bradley R.
    Culm-Merdek, Kerry
    Mockbee, Colleen
    Youssoufian, Hagop
    Stagg, Robert
    Naumann, R. Wendel
    Wenham, Robert M.
    Rosengarten, Rafael D.
    Benjamin, Laura
    Hamilton, Erika Paige
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2568 - +
  • [4] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer
    Backes, F. J.
    Wei, L.
    Cohn, D. E.
    Salani, R.
    Hays, J. L.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
  • [5] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
    Backes, Floor J.
    Wei, Lai
    Chen, Min
    Hill, Kasey
    Dzwigalski, Kyle
    Poi, Ming
    Phelps, Mitch
    Salani, Ritu
    Copeland, Larry J.
    Fowler, Jeffrey M.
    Cohn, David E.
    Bixel, Kristin
    Cosgrove, Casey
    Hays, John
    O'Malley, David
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 619 - 625
  • [6] A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Corr, B.
    Hamilton, E.
    Burger, R. A.
    Wenham, R.
    Naumann, R. W.
    Stagg, R.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] A phase II study of weekly paclitaxel, lenvatinib and pembrolizumab among patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer
    Backes, Floor
    Wei, Lai
    Cosgrove, Casey
    Bixel, Kristin
    Nagel, Christa
    Chambers, Laura
    Cohn, David
    Copeland, Larry
    Hays, John
    Crafton, Sarah
    Myerscough, Callan
    Herman, Molly
    O'Malley, David
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S76 - S76
  • [8] Phase I/II study of weekly paclitaxel with or without alisertib, an investigational aurora a Kinase inhibitor: phase I results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer
    Falchook, G.
    Goff, B.
    Kurzrock, R.
    Gray, H.
    Martin, L.
    Coleman, R.
    Xiao, H.
    Zhou, X.
    Benaim, E.
    Schilder, R.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S31 - S32
  • [9] Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
    Taylor, Sarah E.
    Chu, Tianjiao
    Elvin, Julia A.
    Edwards, Robert P.
    Zorn, Kristin K.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 32 - 37
  • [10] Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Hagemann, Andrea R.
    Novetsky, Akiva P.
    Zighelboim, Israel
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Wright, Jason D.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 535 - 540
12345